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Page 16 of this review contains two errors. We erroneously stated that the range of the hypermutated glioma cases was ‘‘7–450’’; this
should in fact read ‘‘39–249.’’ The correct sentence is as follows: ‘‘Costello’s laboratory performed a comparison of the genomic
landscape of gliomas at initial diagnosis and recurrence and found that 6 of 10 tumors that recurred as glioblastomas, a high-grade
tumor with worse prognosis, displayed evidence of hypermutation—exhibiting 39–249 times the mutational load per megabase
compared with primary gliomas.’’
In addition, for clarity, the legend for Figure 1B should read ‘‘low-grade glioma’’ and not ‘‘glioblastoma tumor.’’ The correct sentence
is as follows: ‘‘The evolution of a low-grade glioma that has undergone treatment with Temozolomide (TMZ).’’Cancer Cell 28, 141, July 13, 2015 ª2015 Elsevier Inc. 141
